Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes

NovoMix® 30 UPGRADE (NovoMix® 30 Use for Progressed Glycemic Control in Realistic Administration to DiabEtes Mellitus): A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Efficacy and Safety Study in Patients Using Biphasic Insulin Aspart 30 (NovoMix® 30) for the Treatment of Diabetes Mellitus

This study is conducted in Asia. The aim of this observational study is to evaluate the efficacy on blood glucose control while using NovoMix® 30 FlexPen® under normal clinical practice conditions in Korea. A clinical safety profile will be also evaluated.

Inclusion Criteria:

• Any patient with type 1 and type 2 diabetes who are treated with NovoMix® 30
• Patient who signed on informed consent form

Exclusion Criteria:

• Patients who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit
• Patients who were previously enrolled in this study
• Patients with a hypersensitivity to NovoMix® 30 or to any of the excipients
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months